Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTJBP9)

Drug Name

PF-670462 Drug Info

Synonyms

950912-80-8; PF 670462; PF670462; UNII-D68ANS5I8B; D68ANS5I8B; 4-[1-Cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-2-pyrimidinamine Dihydrochloride; PF-670462 HCl; 950912-80-8 (HCl); 4-[1-Cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-2-pyrimidinaminedihydrochloride; 4-[1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyrimidin-2-amine dihydrochloride; 4-[3-cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine;dihydrochloride; 4-[3-Cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine dihydrochloride; 4-(1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyrimidin-2-amine dihydrochloride; PF670462 dihydrochloride; cc-367; C19H20FN5.2ClH; C19H20FN5.2HCl; SCHEMBL18921552; CHEBI:87236; AOB3526; DTXSID50679609; BCP04305; EX-A2193; 3966AH; MFCD12828759; AKOS024457546; BCP9000015; CS-1015; QC-8952; 2-Pyrimidinamine, 4-(1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-, hydrochloride (1:2); AC-32583; AK232229; AS-73728; HY-15490; BCP0726000078; FT-0673653; S6734; A11781; S-7816; PF670462/ PF-670462; J-514222; Q27159459; 4-[1-Cyclohexyl-4-(4-fluorophenyl)- 1H-imidazol-5-yl]-2-pyrimidinamine dihydrochloride; 4-[3-cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-aminedihydrochloride; 4-[1-Cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyrimidin-2-amine--hydrogen chloride (1/2)

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Preclinical	[1]

Cross-matching ID

PubChem CID: 51049607
ChEBI ID: CHEBI:87236
CAS Number: CAS 950912-80-8
TTD Drug ID: DMTJBP9

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Preclinical Drug(s)

Investigative Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Casein kinase I delta (CSNK1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IC261	DMXB95R	Pancreatic cancer	2C10	Preclinical	[2]
D-4476	DMHD3R8	Chronic lymphocytic leukaemia	2A82.0	Preclinical	[3]
PF-4800567	DM8P9ST	Chronic lymphocytic leukaemia	2A82.0	Preclinical	[4]
PMID24900428C14	DMU4BL2	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------

Drug(s) Targeting Casein kinase I epsilon (CSNK1E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Umbralisib	DMYRBO1	Follicular lymphoma	2A80	Approved	[6]
IC261	DMXB95R	Pancreatic cancer	2C10	Preclinical	[2]
PF-4800567	DM8P9ST	Chronic lymphocytic leukaemia	2A82.0	Preclinical	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Casein kinase I delta (CSNK1D)	TTH30UI	KC1D_HUMAN	Inhibitor	[1]
Casein kinase I epsilon (CSNK1E)	TTA8PLI	KC1E_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018 Mar 15;131(11):1206-1218.
2	Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000 Jun 30;275(26):20052-60.
3	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
4	Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. J Pharmacol Exp Ther. 2009 Aug;330(2):430-9.
5	Structure-Based Design of Potent and Selective CK1gamma Inhibitors. ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021